TechCrunch Startup News Onepot AI raises $13M to help make chemical drug creation easier
Nov 19, 2025
Discover how OnePot AI aims to revolutionize drug discovery by tackling the synthesis bottleneck that often halts promising ideas. Founders Daniil Boyko and Andre Tiran launched the venture to create a seamless process for making new molecules, likening it to assembling a complex puzzle. They raised $13 million to compress synthesis timelines from months to just days. OnePot's innovative approach integrates advanced AI and meticulous data recording to ensure reproducibility, while addressing supply chain challenges in the U.S. biotech landscape.
AI Snips
Chapters
Transcript
Episode notes
Founders Saw Promising Drugs Abandoned
- Daniil Boyko noticed that many promising drug ideas were abandoned because the molecules were too hard to synthesize.
- He and Andre Tiran founded OnePot to tackle synthesis bottlenecks with a dedicated lab and AI-driven workflows.
Design Outruns The Lab
- Computational models generate molecular ideas much faster than labs can synthesize them, creating a bottleneck.
- OnePot aims to compress synthesis timelines from months to days to align design with execution.
Industrializing Synthesis With Real Experiment Data
- OnePot treats synthesis as a systems problem that can be industrialized with data and automation.
- They capture every experimental detail so AI agents learn from real-world experiments rather than just literature data.